News & Updates

Combination treatment with pembrolizumab and adjuvant radiotherapy (RT) does not pose any serious risk to patients with triple-negative breast cancer (TNBC), showing no increase in radiation-related adverse events (AEs), a study has shown.

Treatment with sacituzumab tirumotecan (sac-TMT) shows a promising antitumour activity and an acceptable safety profile in patients with heavily pretreated advanced or metastatic urothelial carcinoma (UC), according to a phase II study.

Treatment with nirsevimab helps reduce hospitalizations and emergency department (ED) visits associated with lower respiratory tract infections (LRTIs) in infants and young children, according to the results of a meta-analysis.

Most women on antidepressant therapy discontinue their medications during pregnancy despite guideline recommendations against doing so, and this practice results in more mental health emergencies, according to new research.

New drug applications approved by US FDA as of 1-15 February 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

The risk of an inflammatory bowel disease (IBD) flare does not increase in the year after initiating gender-affirming hormone therapy (GAHT), but individuals with IBD prior to hormone start and those receiving testosterone have a higher likelihood of having an IBD flare, a study has shown.

Patients with hepatocellular carcinoma (HCC) who develop immune-related adverse events (irAEs) following treatment with an immune checkpoint inhibitor (ICI) tend to have more favourable clinical outcomes, including better progression free survival (PFS) and objective response rate (ORR), reports a recent study.

In the treatment of patients with diabetes and multivessel disease undergoing percutaneous coronary intervention (PCI), clinical outcomes appear to be better with prasugrel than ticagrelor, according to the TUXEDO-2* study.